单位:[1]First Hosp Jilin Univ, Changchun, Peoples R China[2]Zhengzhou Sixth Peoples Hosp, Zhengzhou, Peoples R China[3]Xinjiang Med Univ, Hosp 1, Urumqi, Peoples R China[4]Liuzhou Peoples Hosp, Liuzhou, Peoples R China[5]Second Hosp Nanjing, Nanjing, Peoples R China[6]Joint Logist Support Force PLA, Hosp 940, Lanzhou, Peoples R China[7]Sixth Peoples Hosp Shenyang, Shenyang, Peoples R China[8]Capital Med Univ, Beijing Friendship Hosp, Beijing, Peoples R China首都医科大学附属北京友谊医院[9]Third Peoples Hosp Zhenjiang, Zhenjiang, Jiangsu, Peoples R China[10]Cent South Univ, Xiangya Hosp, Changsha, Peoples R China[11]Cent South Univ, Xiangya Hosp 2, Changsha, Peoples R China[12]Guangzhou Eighth Peoples Hosp, Guangzhou, Peoples R China[13]Lanzhou Univ, Hosp 1, Lanzhou, Peoples R China[14]Shanghai Publ Hlth Clin Ctr, Shanghai, Peoples R China[15]Qingdao Municipal Hosp, Qingdao, Peoples R China[16]Shulan Hangzhou Hosp, Hangzhou, Peoples R China[17]Capital Med Univ, Beijing Youan Hosp, Beijing, Peoples R China[18]Nanjing Sanhome Pharmaceut Co Ltd, Nanjing, Peoples R China
第一作者单位:[1]First Hosp Jilin Univ, Changchun, Peoples R China
推荐引用方式(GB/T 7714):
Hua Rui,Kong Fei,Li Guangming,et al.A phase 2, open-label study of pan-genotype regimen of SH229 plus daclatasvir in Chinese patients with chronic hepatitis C virus infection[J].JOURNAL of HEPATOLOGY.2020,73:S342-S342.
APA:
Hua, Rui,Kong, Fei,Li, Guangming,Zhang, Yuexin,Wen, Xiaofeng...&Niu, Junqi.(2020).A phase 2, open-label study of pan-genotype regimen of SH229 plus daclatasvir in Chinese patients with chronic hepatitis C virus infection.JOURNAL of HEPATOLOGY,73,
MLA:
Hua, Rui,et al."A phase 2, open-label study of pan-genotype regimen of SH229 plus daclatasvir in Chinese patients with chronic hepatitis C virus infection".JOURNAL of HEPATOLOGY 73.(2020):S342-S342